CASC2 and ovarian carcinoma: Ovarian cancer, often termed the “silent killer” due to its high mortality rate, shows promising response to SNG in epithelial ovarian cancer cells by controlling the CASC2-EIF4A3 axis, blocking NF-κB signaling, or the PI3K/AKT/mTOR pathway (Zhang et al., 2018).